The reference Type II 5AR inhibitor, mature and well-characterized, with real probe value but limited novelty
Look, finasteride is a 30-year-old approved drug with a completely characterized mechanism. That’s not a knock on it, thats just what it is. FDA cleared in 1992 for BPH and 1997 for androgenetic alopecia, it became the reference standard Type II-selective 5-alpha-reductase inhibitor in androgen biology research, and that’s the best argument for including it in a research library at all.
The mechanism is specific: finasteride inhibits the Type II isozyme (Ki approximately 10 nM) without meaningfully touching Type I, which lives in liver, skin, and the brain. Dutasteride hits both, dropping plasma DHT by around 95 percent. That gap is actually what makes finasteride interesting on the bench, not therapeutically, but as a probe. If you want to ask what Type I versus Type II 5AR contributes to a given phenotype, finasteride is your tool. That question comes up in androgen pathway work, in skin biology, and increasingly in neurosteroid research.
The neurosteroid angle is genuinely the most interesting current research use. Finasteride inhibits the conversion of progesterone to 5-alpha-dihydroprogesterone, which is upstream of allopregnanolone synthesis. Allopregnanolone is a positive GABA-A allosteric modulator, and its reduction is one proposed mechanism behind what is now called post-finasteride syndrome (PFS). We dont want to over-claim here, the literature is contested and the mechanistic case is still being built, but the neurosteroid deprivation hypothesis has generated serious laboratory work, including papers from the Melcangi group at the University of Milan examining central nervous system steroid profiles after finasteride exposure in rodent models. Thats real bench science with real questions still open.
What works against a high score is straightforward: the compound isn’t novel, the core mechanism is completely solved, and for pure androgen pathway intervention dutasteride offers a more complete picture. Finasteride is useful because it’s the Type II selective option, not because it’s doing anything pharmacologically surprising. Its evidence quality and translational signal are excellent precisely because it’s a mature approved drug with decades of large-scale human data. Those scores pull the overall up, but they shouldn’t, because well-characterized evidence on a boring old mechanism isn’t research excitement.
We think of finasteride as a mature tool with a specific probe niche. It earns a spot as the reference Type II 5AR inhibitor and as a gateway into the PFS neurosteroid literature, but it’s not a compound that any serious investigator has on their want-to-study-more list in 2025 unless the question is specifically about Type I versus Type II isozyme contributions or GABA-A neurosteroid circuitry.